Keryx Investors Seek Class Cert. In Kidney Drug Stock Case
By Hailey Konnath ( April 30, 2019, 10:36 PM EDT) -- A Keryx Biopharmaceuticals Inc. investor on Tuesday urged a Massachusetts federal judge to certify a class of shareholders he claims lost money after the company allegedly concealed potential problems with manufacturing its kidney disease-fighting drug Auryxia....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.